ADC Therapeutics highlights ZYNLONTA growth opportunity in corporate presentation
Reuters2026/09/10 15:18- ADC Therapeutics highlighted ZYNLONTA growth ambitions, targeting a multi-billion-dollar US opportunity across 2L+ DLBCL and 2L+ indolent lymphomas.
- LOTIS-5 Phase 3 met its primary PFS endpoint: HR 0.73, p 0.0084; median PFS 6.14 months vs 4.73 months.
- Complete responses improved to 40% from 27%; 24-month CR durability 48.5% vs 16.7%.
- Overall survival showed no detriment: HR 0.96; median OS 12.19 months vs 12.16 months.
- Safety profile mixed: Grade 5 TEAEs 13.2% vs 4.6%; hematologic Grade ≥3 TEAEs higher with R-GemOx.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cantex Mine Development closes second tranche of private placement for $1.01 million proceeds
PVH CEO Stefan Larsson acquires USD 999,999 of common shares
The rebound of the yen may only be temporary, Morgan Stanley bets on arbitrage trades making a comeback, USD/JPY expected to rise to 163.
Morgan Stanley believes that the recent strengthening of the Japanese yen is mainly due to the unwinding of short-term arbitrage trades and market bets on Japanese capital repatriation, rather than any substantial improvement in fundamentals.
Edwards Lifesciences CVP, TAVR Daniel J. Lippis disposes of 619 common shares worth $54,168.69
Crypto prices
More
